332 related articles for article (PubMed ID: 36902639)
21. The Significance of the Mediterranean Diet in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review.
Gosal H; Kaur H; Chakwop Ngassa H; Elmenawi KA; Anil V; Mohammed L
Cureus; 2021 Jun; 13(6):e15618. PubMed ID: 34277236
[TBL] [Abstract][Full Text] [Related]
22. Beyond Body Weight-Loss: Dietary Strategies Targeting Intrahepatic Fat in NAFLD.
Worm N
Nutrients; 2020 May; 12(5):. PubMed ID: 32384593
[TBL] [Abstract][Full Text] [Related]
23. Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations.
Arrese M; Barrera F; Triantafilo N; Arab JP
Expert Rev Gastroenterol Hepatol; 2019 Sep; 13(9):849-866. PubMed ID: 31353974
[No Abstract] [Full Text] [Related]
24. Weight reduction for non-alcoholic fatty liver disease.
Peng L; Wang J; Li F
Cochrane Database Syst Rev; 2011 Jun; (6):CD003619. PubMed ID: 21678341
[TBL] [Abstract][Full Text] [Related]
25. Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease.
Kim KS; Lee BW
Clin Mol Hepatol; 2020 Oct; 26(4):430-443. PubMed ID: 32791578
[TBL] [Abstract][Full Text] [Related]
26. Effects of Dietary and Lifestyle Interventions on Liver, Clinical and Metabolic Parameters in Children and Adolescents with Non-Alcoholic Fatty Liver Disease: A Systematic Review.
Katsagoni CN; Papachristou E; Sidossis A; Sidossis L
Nutrients; 2020 Sep; 12(9):. PubMed ID: 32961669
[TBL] [Abstract][Full Text] [Related]
27. Calorie-Restricted Mediterranean and Low-Fat Diets Affect Fatty Acid Status in Individuals with Nonalcoholic Fatty Liver Disease.
Ristic-Medic D; Kovacic M; Takic M; Arsic A; Petrovic S; Paunovic M; Jovicic M; Vucic V
Nutrients; 2020 Dec; 13(1):. PubMed ID: 33374554
[TBL] [Abstract][Full Text] [Related]
28. The effect of dietary patterns on non-alcoholic fatty liver disease diagnosed by biopsy or magnetic resonance in adults: a systematic review of randomised controlled trials.
Angelidi AM; Papadaki A; Nolen-Doerr E; Boutari C; Mantzoros CS
Metabolism; 2022 Apr; 129():155136. PubMed ID: 35032545
[TBL] [Abstract][Full Text] [Related]
29. A multi-targeting strategy to ameliorate high-fat-diet- and fructose-induced (western diet-induced) non-alcoholic fatty liver disease (NAFLD) with supplementation of a mixture of legume ethanol extracts.
Koh YC; Lin YC; Lee PS; Lu TJ; Lin KY; Pan MH
Food Funct; 2020 Sep; 11(9):7545-7560. PubMed ID: 32815965
[TBL] [Abstract][Full Text] [Related]
30. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention.
Tacke F; Weiskirchen R
Ann Transl Med; 2021 Apr; 9(8):729. PubMed ID: 33987427
[TBL] [Abstract][Full Text] [Related]
31. Polyphenols in the prevention and treatment of non-alcoholic fatty liver disease: An update of preclinical and clinical studies.
Bayram HM; Majoo FM; Ozturkcan A
Clin Nutr ESPEN; 2021 Aug; 44():1-14. PubMed ID: 34330452
[TBL] [Abstract][Full Text] [Related]
32. Effect of a counseling-supported treatment with the Mediterranean diet and physical activity on the severity of the non-alcoholic fatty liver disease.
Gelli C; Tarocchi M; Abenavoli L; Di Renzo L; Galli A; De Lorenzo A
World J Gastroenterol; 2017 May; 23(17):3150-3162. PubMed ID: 28533672
[TBL] [Abstract][Full Text] [Related]
33. Evaluations of Lifestyle, Dietary, and Pharmacologic Treatments for Pediatric Nonalcoholic Fatty Liver Disease: A Systematic Review.
Mann JP; Tang GY; Nobili V; Armstrong MJ
Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1457-1476.e7. PubMed ID: 29857146
[TBL] [Abstract][Full Text] [Related]
34. Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial.
Yoneda M; Honda Y; Ogawa Y; Kessoku T; Kobayashi T; Imajo K; Ozaki A; Nogami A; Taguri M; Yamanaka T; Kirikoshi H; Iwasaki T; Kurihashi T; Saito S; Nakajima A
BMJ Open Diabetes Res Care; 2021 Feb; 9(1):. PubMed ID: 33593749
[TBL] [Abstract][Full Text] [Related]
35. Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial.
Jazayeri-Tehrani SA; Rezayat SM; Mansouri S; Qorbani M; Alavian SM; Daneshi-Maskooni M; Hosseinzadeh-Attar MJ
Nutr Metab (Lond); 2019; 16():8. PubMed ID: 30705687
[TBL] [Abstract][Full Text] [Related]
36. [An interpretation of the AASLD practice guideline on the diagnosis and management of nonalcoholic fatty liver disease in 2017].
Nan YM; Fu N; Li WC; Kong LL; Yuan XW; Zhang SY; Liu LD; Lu Y; Cui LY
Zhonghua Gan Zang Bing Za Zhi; 2017 Sep; 25(9):687-694. PubMed ID: 29108191
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice.
Zhou ST; Cui W; Kong L; Yang X
Curr Med Sci; 2022 Jun; 42(3):513-519. PubMed ID: 35451807
[TBL] [Abstract][Full Text] [Related]
38. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss.
Pouwels S; Sakran N; Graham Y; Leal A; Pintar T; Yang W; Kassir R; Singhal R; Mahawar K; Ramnarain D
BMC Endocr Disord; 2022 Mar; 22(1):63. PubMed ID: 35287643
[TBL] [Abstract][Full Text] [Related]
39. Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial.
Yoneda M; Kobayashi T; Honda Y; Ogawa Y; Kessoku T; Imajo K; Nogami A; Taguri M; Kirikoshi H; Saito S; Nakajima A
Hepatol Commun; 2022 Sep; 6(9):2273-2285. PubMed ID: 35578445
[TBL] [Abstract][Full Text] [Related]
40. Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update.
Barchetta I; Cimini FA; Cavallo MG
Nutrients; 2020 Oct; 12(11):. PubMed ID: 33126575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
